Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 17 results.
User Information
Export Records
  1. 1.   Long-acting rilpivirine (RPV LA) pre-exposure prophylaxis does not inhibit vaginal transmission of RPV-resistant HIV-1 nor select for high frequency drug resistance in humanized mice
  2. Melody, Kevin; Roy, Chandra N; Kline, Christopher; Cottrell, Mackenzie L; Evans, Dwayne; Shutt, Kathleen; Pennings, Pleuni S; Keele,Brandon; Bility, Moses; Kashuba, Angela D M; Ambrose, Zandrea
  3. Journal of virology. 2020, APR; 94(8):
  1. 2.   Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors
  2. Wu, Yumeng; Tang, Chengrun; Rui, Ruomei; Yang, Liumeng; Ding, Wei; Wang, Jiangyuan; Li, Yiming; Lai,Christopher; Wang, Yueping; Luo, Ronghua; Xiao, Weilie; Zhang, Hongbing; Zheng, Yongtang; He, Yanping
  3. Acta pharmaceutica Sinica. B. 2020, Mar; 10(3): 512-528.
  1. 3.   Molecular insight into the interaction mechanisms of an annulated pyrazole (DB08446) with HIV-1 RT: a QM and QM/QM' study
  2. Wang, Yueping; Wang, Jiangyuan; Zhong, Peng; Li, Yiming; Lai, Christopher; He, Yanping
  3. MONATSHEFTE FUR CHEMIE. 2018, Oct; 149(10): 1919-1929.
  1. 4.   A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity
  2. Urano, E.; Miyauchi, K.; Kojima, Y.; Hamatake, M.; Ablan, S. D.; Fudo, S.; Freed, E. O.; Hoshino, T.; Komano, J.
  3. Chemmedchem. 2016, 19-Oct; 11(20): 2320-2326.
  1. 5.   The effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TC
  2. Davis, C. A.; Parniak, M. A.; Hughes, S. H.
  3. Virology. 2011, Oct; 419(2): 64-71.
  1. 6.   Prevalence of Etravirine-Associated Mutations in Clinical Samples With Genotypic Resistance to Nevirapine and Efavirenz in Brazilian Clinics
  2. Martins, A. N.; Arruda, M. B.; Aleixo, A. W.; Pires, A. F.; Greco, D. B.; Brindeiro, R. D.; Tanuri, A.
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2011, Aug; 57: S193-S196.
  1. 7.   Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents
  2. He, Y. P.; Long, J.; Zhang, S. S.; Li, C.; Lai, C. C.; Zhang, C. S.; Li, D. X.; Zhang, D. H.; Wang, H.; Cai, Q. Q.; Zheng, Y. T.
  3. Bioorganic & Medicinal Chemistry Letters. 2011, Jan; 21(2): 694-697.
  1. 8.   The "Connection" Between HIV Drug Resistance and RNase H
  2. Delviks-Frankenberry, K. A.; Nikolenko, G. N.; Pathak, V. K.
  3. Viruses-Basel. 2010, Jul; 2(7): 1476-1503.
  1. 9.   HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision
  2. Delviks-Frankenberry, K. A.; Nikolenko, G. N.; Boyer, P. L.; Hughes, S. H.; Coffin, J. M.; Jere, A.; Pathak, V. K.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2008 105(31): 10943-10948.
  1. 10.   Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
  2. Palmer, S.; Boltz, V.; Maldarelli, F.; Kearney, M.; Halvas, E. K.; Rock, D.; Falloon, J.; Davey, R. T.; Dewar, R. L.; Metcalf, J. A.; Mellors, J. W.; Coffin, J. M.
  3. Aids. 2006, Mar; 20(5): 701-710.
  1. 11.   Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: A new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains
  2. Himmel, D. M.; Das, K.; Clark, A. D.; Hughes, S. H.; Benjahad, A.; Oumouch, S.; Guillemont, J.; Coupa, S.; Poncelet, A.; Csoka, I.; Meyer, C.; Andries, K.; Nguyen, C. H.; Grierson, D. S.; Arnold, E.
  3. Journal of Medicinal Chemistry. 2005, DEC 1; 48(24): 7582-7591.
  1. 12.   Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors
  2. Das, K.; Lewi, P. J.; Hughes, S. H.; Arnold, E.
  3. Progress in Biophysics and Molecular Biology. 2005, JUN; 88(2): 209-231.
  1. 13.   The level of RT in HIV-1 particles affects susceptibility to NNRTIs but not to 3TC
  2. Ambrose, Z.; Julias, J. G.; Boyer, P. L.; KewalRamani, V. N.; Hughes, S. H.
  3. Antiviral Therapy. 2005 10(4): S96-S96.
  1. 14.   In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques
  2. Ambrose, Z.; Boltz, V.; Palmer, S.; Coffin, J. M.; Hughes, S. H.; KewalRamani, V. N.
  3. Journal of Virology. 2004, DEC; 78(24): 13553-13561.
  1. 15.   Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA
  2. Peletskaya, E. N.; Kogon, A. A.; Tuske, S.; Arnold, E.; Hughes, S. H.
  3. Journal of Virology. 2004 78(7): 3387-3397.
  1. 16.   Synthesis of a Non-Nucleoside Reverse Transcriptase Inhibitor in the Alkenyldiarylmethane (Adam) Series With Optimized Potency and Therapeutic Index
  2. Cushman, M.; Casimirogarcia, A.; Williamson, K.; Rice, W. G.
  3. Bioorganic & Medicinal Chemistry Letters. 1998 8(2): 195-198.
  1. 17.   3D-QSAR Studies of S-DABO Derivatives as Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors
  2. Wang, Yueping; Chang, Jie; Wang, Jiangyuan; Zhong, Peng; Zhang, Yufang; Lai,Christopher; Hez, Yanping
  3. LETTERS IN DRUG DESIGN & DISCOVERY. 2019 16(8): 868-881.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel